Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer

Cancer Treat Res. 1994:71:299-309. doi: 10.1007/978-1-4615-2592-9_16.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Breast Neoplasms / enzymology
  • Breast Neoplasms / pathology
  • Breast Neoplasms / physiopathology*
  • Female
  • Humans
  • Metalloendopeptidases / physiology*
  • Neoplasm Invasiveness
  • Plasminogen Activator Inhibitor 1 / physiology*
  • Prognosis
  • Serine Endopeptidases / physiology*
  • Urokinase-Type Plasminogen Activator / antagonists & inhibitors
  • Urokinase-Type Plasminogen Activator / physiology*

Substances

  • Plasminogen Activator Inhibitor 1
  • Serine Endopeptidases
  • Urokinase-Type Plasminogen Activator
  • Metalloendopeptidases